Last reviewed 2026-04-19 · How we verify

LAUROGUADINE

Phase 2 active Small molecule

LAUROGUADINE is a lauroguadine drug. It is currently in Phase 2 development.

Lauroguadine works by interacting with a specific biological target to produce its therapeutic effect.

Lauroguadine is a small molecule drug in the lauroguadine class, originally developed by an unknown entity. Its current owner is also unknown. The target and approved indications of lauroguadine are not specified. The commercial status of lauroguadine is unclear, and it is unknown whether it is patented or available as a generic. Further information on its pharmacokinetic properties and safety considerations is also lacking.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	LAUROGUADINE
Drug class	lauroguadine
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

In simple terms, lauroguadine is thought to bind to a particular protein or receptor in the body, which helps to regulate a specific process or function. This binding action triggers a series of downstream effects that ultimately lead to the desired therapeutic outcome.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LAUROGUADINE CI brief — competitive landscape report
LAUROGUADINE updates RSS · CI watch RSS

Frequently asked questions about LAUROGUADINE

What is LAUROGUADINE?

LAUROGUADINE is a lauroguadine drug.

How does LAUROGUADINE work?

Lauroguadine works by interacting with a specific biological target to produce its therapeutic effect.

What drug class is LAUROGUADINE in?

LAUROGUADINE belongs to the lauroguadine class. See all lauroguadine drugs at /class/lauroguadine.

What development phase is LAUROGUADINE in?

LAUROGUADINE is in Phase 2.

Drug class: All lauroguadine drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing